PAF antagonism approach treatment airway hyperreactivity Platelet-activating factor PAF good candidate mediator airway hyperreactivity long-lasting modest increase hyperreactivity experimental animals humans Evidence indirect increased levels bronchial hyperreactivity related late-phase reaction asthma experimental animals specific inhibitors PAF allergen PAF-induced hyperreactivity late-phase reaction mechanism PAF induces hyperreactivity unknown potent effects PAF eosinophil cell characteristic inflammatory asthma hyperreactivity important number potent selective PAF antagonists available crucial test hypothesis PAF role human airway hyperreactivity testing substances appropriate double-blind placebo-controlled clinical trials 